IL159714A0 - 5-cnac as oral delivery agent for parathyroid hormone fragments - Google Patents

5-cnac as oral delivery agent for parathyroid hormone fragments

Info

Publication number: IL159714A0
Authority: IL; Israel
Prior art keywords: parathyroid hormone; oral delivery; cnac; delivery agent; hormone fragments
Prior art date: 2001-08-17

Application number

IL15971402A

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-17

Filing date

2002-08-16

Publication date

2004-06-20

2002-08-16 Application filed by Novartis Ag filed Critical Novartis Ag

2004-06-20 Publication of IL159714A0 publication Critical patent/IL159714A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL15971402A 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments IL159714A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31304801P	2001-08-17	2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en)	2001-08-17	2002-08-16	5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (1)

Publication Number	Publication Date
IL159714A0 true IL159714A0 (en)	2004-06-20

Family

ID=23214149

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL15971402A IL159714A0 (en)	2001-08-17	2002-08-16	5-cnac as oral delivery agent for parathyroid hormone fragments
IL159714A IL159714A (en)	2001-08-17	2004-01-05	Pharmaceutical composition for oral delivery comprising a fragment of parathyroid hormone and 5-cnac

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL159714A IL159714A (en)	2001-08-17	2004-01-05	Pharmaceutical composition for oral delivery comprising a fragment of parathyroid hormone and 5-cnac

Country Status (26)

Country	Link
US (4)	US20040242478A1 (no)
EP (1)	EP1420827B8 (no)
JP (2)	JP4959917B2 (no)
KR (1)	KR20040030120A (no)
CN (1)	CN1279981C (no)
AT (1)	ATE443527T1 (no)
AU (1)	AU2002333443C1 (no)
BR (1)	BRPI0211932B1 (no)
CA (1)	CA2453646C (no)
CO (1)	CO5560586A2 (no)
CY (1)	CY1109661T1 (no)
DE (1)	DE60233803D1 (no)
DK (1)	DK1420827T3 (no)
EC (1)	ECSP044961A (no)
ES (1)	ES2333587T3 (no)
HU (1)	HUP0401441A3 (no)
IL (2)	IL159714A0 (no)
MX (1)	MXPA04001418A (no)
NO (1)	NO328069B1 (no)
NZ (1)	NZ531018A (no)
PL (1)	PL210258B1 (no)
PT (1)	PT1420827E (no)
RU (1)	RU2322256C2 (no)
SI (1)	SI1420827T1 (no)
WO (1)	WO2003015822A1 (no)
ZA (1)	ZA200400242B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ307145B6 (cs) *	2001-06-01	2018-02-07	Novartis Ag	Kompozice pro orální podání, použití této kompozice a souprava pro stimulaci nové kostní tvorby
ATE443527T1 (de) *	2001-08-17	2009-10-15	Novartis Pharma Gmbh	5-cnac zur oralen verabreichung von parathormonfragmenten
DE60318192T2 (de) *	2002-04-10	2008-04-30	The University Of Virginia Patent Foundation	Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US20050054557A1 (en) *	2002-05-09	2005-03-10	Goldberg Michael M.	Compositions for delivering parathyroid hormone and calcitonin
TWI343816B (en)	2003-07-23	2011-06-21	Novartis Ag	Use of calcitonin in osteoarthritis
GB0427600D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
US8110547B2 (en) *	2005-01-12	2012-02-07	Emisphere Technologies, Inc.	Compositions for buccal delivery of parathyroid hormone
EP1896134A2 (en) *	2005-06-13	2008-03-12	Rigel Pharmaceuticals, Inc.	Methods and compositions for treating degenerative bone disorders
TWI386386B (zh)	2005-09-19	2013-02-21	Emisphere Tech Inc	Ｎ-（５-氯柳醯基）-８-胺基辛酸之二鈉鹽的晶形
GB0522566D0 (en) *	2005-11-04	2005-12-14	Novartis Ag	Organic compounds
CA2628945A1 (en) *	2005-11-10	2007-05-24	Board Of Control Of Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CA2661521C (en) *	2006-08-31	2016-04-12	Novartis Ag	Pharmaceutical compositions comprising hgh for oral delivery
PL2131810T3 (pl)	2007-03-02	2011-09-30	Novartis Ag	Podawanie doustne kalcytoniny
BRPI0817396C8 (pt)	2007-11-02	2021-05-25	Emisphere Tech Inc	composição farmacêutica para tratar deficiência de vitamina b¹²
JP2013512688A (ja)	2009-12-07	2013-04-18	ミシガンテクノロジカルユニバーシティ	クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
WO2012130193A1 (en)	2011-03-31	2012-10-04	Zentiva, K.S.	Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
US20180050096A1 (en) *	2015-02-09	2018-02-22	Entera Bio Ltd.	Treatment of hypoparathyroidism
KR101796604B1 (ko) *	2016-08-30	2017-11-10	목포대학교 산학협력단	위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4692433A (en) *	1983-10-12	1987-09-08	The Regents Of The University Of California	Method and composition for regulating serum calcium levels of mammals
AU3322593A (en) *	1991-12-17	1993-07-19	Procter & Gamble Pharmaceuticals, Inc.	Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
EP0679088B1 (en) *	1992-09-29	2002-07-10	Inhale Therapeutic Systems	Pulmonary delivery of active fragments of parathyroid hormone
US5773647A (en) *	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
DK0993831T3 (da) *	1997-02-07	2008-03-25	Emisphere Tech Inc	Forbindelser og præparater til tilförsel af aktive stoffer
ATE384743T1 (de) *	1998-11-25	2008-02-15	Gen Hospital Corp	Aminoterminal modifizierte parathyroidhormon (pth) analoge
WO2000059863A1 (en) *	1999-04-05	2000-10-12	Emisphere Technologies, Inc.	Disodium salts, monohydrates, and ethanol solvates
JP4799794B2 (ja) *	2000-03-21	2011-10-26	エミスフェアー・テクノロジーズ・インク	ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
CZ307145B6 (cs) *	2001-06-01	2018-02-07	Novartis Ag	Kompozice pro orální podání, použití této kompozice a souprava pro stimulaci nové kostní tvorby
ATE443527T1 (de) *	2001-08-17	2009-10-15	Novartis Pharma Gmbh	5-cnac zur oralen verabreichung von parathormonfragmenten
ATE442158T1 (de) *	2003-07-11	2009-09-15	Novartis Pharma Gmbh	Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form

2002
- 2002-08-16 AT AT02794796T patent/ATE443527T1/de active
- 2002-08-16 PT PT02794796T patent/PT1420827E/pt unknown
- 2002-08-16 US US10/484,331 patent/US20040242478A1/en not_active Abandoned
- 2002-08-16 EP EP02794796A patent/EP1420827B8/en not_active Expired - Lifetime
- 2002-08-16 SI SI200230866T patent/SI1420827T1/sl unknown
- 2002-08-16 DE DE60233803T patent/DE60233803D1/de not_active Expired - Lifetime
- 2002-08-16 MX MXPA04001418A patent/MXPA04001418A/es active IP Right Grant
- 2002-08-16 BR BRPI0211932A patent/BRPI0211932B1/pt not_active IP Right Cessation
- 2002-08-16 DK DK02794796T patent/DK1420827T3/da active
- 2002-08-16 WO PCT/EP2002/009181 patent/WO2003015822A1/en active Application Filing
- 2002-08-16 PL PL365388A patent/PL210258B1/pl unknown
- 2002-08-16 JP JP2003520780A patent/JP4959917B2/ja not_active Expired - Fee Related
- 2002-08-16 NZ NZ531018A patent/NZ531018A/xx not_active IP Right Cessation
- 2002-08-16 KR KR10-2004-7002277A patent/KR20040030120A/ko active Search and Examination
- 2002-08-16 HU HU0401441A patent/HUP0401441A3/hu unknown
- 2002-08-16 CA CA002453646A patent/CA2453646C/en not_active Expired - Lifetime
- 2002-08-16 CN CNB028160843A patent/CN1279981C/zh not_active Expired - Fee Related
- 2002-08-16 RU RU2004107899/15A patent/RU2322256C2/ru not_active IP Right Cessation
- 2002-08-16 ES ES02794796T patent/ES2333587T3/es not_active Expired - Lifetime
- 2002-08-16 AU AU2002333443A patent/AU2002333443C1/en not_active Ceased
- 2002-08-16 IL IL15971402A patent/IL159714A0/xx unknown
2004
- 2004-01-05 IL IL159714A patent/IL159714A/en not_active IP Right Cessation
- 2004-01-13 ZA ZA200400242A patent/ZA200400242B/en unknown
- 2004-01-29 EC EC2004004961A patent/ECSP044961A/es unknown
- 2004-02-10 NO NO20040598A patent/NO328069B1/no not_active IP Right Cessation
- 2004-02-17 CO CO04013136A patent/CO5560586A2/es not_active Application Discontinuation
2006
- 2006-05-30 US US11/443,528 patent/US20060217313A1/en not_active Abandoned
2009
- 2009-06-09 JP JP2009138067A patent/JP2009242410A/ja not_active Withdrawn
- 2009-07-01 US US12/495,966 patent/US20090264367A1/en not_active Abandoned
- 2009-11-25 CY CY20091101231T patent/CY1109661T1/el unknown
2011
- 2011-12-15 US US13/327,114 patent/US9272040B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2333587T3 (es)	2010-02-24
CY1109661T1 (el)	2014-08-13
CN1543357A (zh)	2004-11-03
JP4959917B2 (ja)	2012-06-27
BR0211932A (pt)	2004-10-26
PL210258B1 (pl)	2011-12-30
US20090264367A1 (en)	2009-10-22
RU2322256C2 (ru)	2008-04-20
BRPI0211932B1 (pt)	2016-12-06
NZ531018A (en)	2006-03-31
KR20040030120A (ko)	2004-04-08
ZA200400242B (en)	2004-11-18
JP2009242410A (ja)	2009-10-22
HUP0401441A3 (en)	2012-09-28
RU2004107899A (ru)	2005-05-10
JP2005501852A (ja)	2005-01-20
DE60233803D1 (de)	2009-11-05
CA2453646C (en)	2008-09-30
EP1420827A1 (en)	2004-05-26
EP1420827B1 (en)	2009-09-23
ATE443527T1 (de)	2009-10-15
AU2002333443C1 (en)	2009-10-08
SI1420827T1 (sl)	2010-01-29
CO5560586A2 (es)	2005-09-30
CA2453646A1 (en)	2003-02-27
CN1279981C (zh)	2006-10-18
EP1420827B8 (en)	2009-12-23
US20120088725A1 (en)	2012-04-12
US20040242478A1 (en)	2004-12-02
US9272040B2 (en)	2016-03-01
DK1420827T3 (da)	2009-12-21
ECSP044961A (es)	2004-03-23
MXPA04001418A (es)	2004-05-27
IL159714A (en)	2010-12-30
AU2002333443B2 (en)	2006-06-29
NO20040598L (no)	2004-02-10
HUP0401441A2 (hu)	2004-12-28
US20060217313A1 (en)	2006-09-28
NO328069B1 (no)	2009-11-23
PT1420827E (pt)	2009-12-15
WO2003015822A1 (en)	2003-02-27
PL365388A1 (en)	2005-01-10

Publication	Publication Date	Title
IL159714A0 (en)	2004-06-20	5-cnac as oral delivery agent for parathyroid hormone fragments
MXPA03007837A (es)	2004-03-16	Composiciones para suministrar bisfosfonatos.
MXPA06012980A (es)	2007-06-12	Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
IL159996A0 (en)	2004-06-20	Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
ZA200405657B (en)	2005-08-29	Formulation & dosage form for the controlled delivery of therapeutic agents.
MXPA04008068A (es)	2004-11-26	Metodo para administrar moleculas de glp-1.
WO2002041837A3 (en)	2003-03-06	Treatment of mucositis
FR06C0032I1 (no)	2006-11-24
GT199700009AA (es)	1999-01-23	Terapia combinada para la osteoporosis
IL158777A0 (en)	2004-05-12	Orally administering parathyroid hormone and calcitonin
TW200511999A (en)	2005-04-01	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
PL370361A1 (en)	2005-05-16	Alkyl urea retinoid agonists i
UA66932C2 (en)	2004-06-15	Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
WO2002074315A8 (de)	2004-06-03	Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
PL370459A1 (en)	2005-05-30	Substituted urea retinoid agonists ii
AU2003286617A8 (en)	2004-06-03	Calcitonin drug-oligomer conjugates, and uses thereof
MXPA05000978A (es)	2005-12-12	Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.
MXPA03006157A (es)	2003-09-16	Metodo de terapia de reemplazo de hormona y su forma de administracion.
IL166678A0 (en)	2006-01-15	17?-estradiol/levonorgestrel transderm patch for hormone replacement therapy
MXPA05003633A (es)	2005-12-14	2"-oxo-voruscharina y derivados de la misma.
WO2000050022A3 (en)	2001-02-01	Treatment regimen for hormone-sensitive cancers
EP1408043A8 (en)	2004-06-16	2''oxo-voruscharin and analogues thereof
TW200509960A (en)	2005-03-16	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
TW200519078A (en)	2005-06-16	2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture